Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Profitability
This table compares Adaptimmune Therapeutics and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adaptimmune Therapeutics | -25.43% | -74.15% | -15.09% |
| Scinai Immunotherapeutics | N/A | N/A | -30.48% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Adaptimmune Therapeutics and Scinai Immunotherapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adaptimmune Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| Scinai Immunotherapeutics | 0 | 0 | 0 | 0 | 0.00 |
Institutional and Insider Ownership
31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Adaptimmune Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.
Valuation & Earnings
This table compares Adaptimmune Therapeutics and Scinai Immunotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adaptimmune Therapeutics | $60.28 million | 2.46 | -$113.87 million | ($0.22) | -2.64 |
| Scinai Immunotherapeutics | N/A | N/A | -$6.50 million | ($239.17) | -0.01 |
Scinai Immunotherapeutics has lower revenue, but higher earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Scinai Immunotherapeutics beats Adaptimmune Therapeutics on 7 of the 13 factors compared between the two stocks.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
